<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00756600</url>
  </required_header>
  <id_info>
    <org_study_id>06-07-0320</org_study_id>
    <nct_id>NCT00756600</nct_id>
  </id_info>
  <brief_title>A Multi-site Randomized Controlled Trial Comparing Regional and General Anesthesia for Effects on Neurodevelopmental Outcome and Apnea in Infants</brief_title>
  <acronym>GAS</acronym>
  <official_title>A Multi-site Randomised Controlled Trial Comparing Regional and General Anaesthesia for Effects on Neurodevelopmental Outcome and Apnoea in Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Murdoch Childrens Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the GAS study is to determine whether different types of anesthesia
      (Regional versus General) given to 720 infants undergoing inguinal hernia repair results in
      equivalent neurodevelopmental outcomes. The study also aims to describe the incidence of
      apnea in the post-operative period after both regional and general anesthesia for inguinal
      hernia repair in infants. This study is important as it will provide the greatest evidence
      for safety or toxicity of general anesthesia for human infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, observer blind, multi-site, randomized, controlled, equivalence trial.
      The general anesthesia group will receive sevoflurane (intervention drug) for induction and
      maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus
      bupivacaine local anesthetic blockade (up to 2.5 mg per kg) administered via caudal or
      ilioinguinal nerve block. The airway can be maintained with a face mask, laryngeal mask or
      endotracheal tube, with or without neuromuscular blocking agents.

      The regional group will have no sedative agent. The regional blockade may be with spinal
      alone, spinal block with caudal block, spinal with ilioinguinal block or caudal alone. The
      maximum dose of 2.5 mg per kg of bupivacaine can be used.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 23, 2006</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Full Scale IQ Score</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>The primary outcome will be the Wechsler Preschool and Primary Scale of Intelligence-Third Edition (WPPSI-III) full scale IQ score. Verbal, visuo-spatial and processing speed skills are incorporated into the Full Scale IQ score, which is indicative of general intellectual ability.
Minimum score: 45 Maximum score:145 Higher scores are associated with higher IQ scores (better outcome).
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Verbal IQ</measure>
    <time_frame>At 5 years corrected age.</time_frame>
    <description>Wechsler Preschool and Primary Scale of Intelligence, Third Edition (WPPSI-III): Verbal IQ
Minimum possible score:45 Maximum possible score:145
A higher score indicates higher verbal IQ (better outcome).
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance IQ</measure>
    <time_frame>At 5 years corrected age</time_frame>
    <description>Wechsler Preschool and Primary Scale of Intelligence, Third Edition (WPPSI-III): Performance IQ
Minimum possible score:45 Maximum possible score:145
A higher score indicates a higher performance IQ (better outcome).
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Processing Speed Quotient</measure>
    <time_frame>At 5 years corrected age</time_frame>
    <description>Wechsler Preschool and Primary Scale of Intelligence, Third Edition (WPPSI-III): Processing speed quotient
Minimum possible score:45 Maximum possible score:145
A higher score indicates a better outcome.
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sentence Repetition Scaled Score</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Developmental Neuropsychological Assessment second edition (NEPSY-II) sub test: Sentence Repetition scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Auditory Attention Combined Scaled Score</measure>
    <time_frame>At 5 years corrected age</time_frame>
    <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Auditory Attention combined scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statue Scaled Score</measure>
    <time_frame>At 5 years corrected age</time_frame>
    <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Statue scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibition Combined Scaled Score</measure>
    <time_frame>At 5 years corrected age</time_frame>
    <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Inhibition combined scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Word Generation Scaled Score</measure>
    <time_frame>At 5 years corrected age</time_frame>
    <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Word Generation Scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Affect Recognition Scaled Score</measure>
    <time_frame>At 5 years corrected age</time_frame>
    <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Affect Recognition scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Memory for Names and Memory for Names Delay</measure>
    <time_frame>At 5 years corrected age</time_frame>
    <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Memory for Names and Memory for Names Delay
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Theory of Mind Scaled Score</measure>
    <time_frame>At 5 years corrected age</time_frame>
    <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Theory of Mind scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speeded Naming Combined Scaled Score</measure>
    <time_frame>At 5 years corrected age</time_frame>
    <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Speeded Naming combined scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fingertip Tapping Repetitions Scaled Score</measure>
    <time_frame>At 5 years corrected age</time_frame>
    <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test:Fingertip tapping repetitions scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score is indicative of a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fingertip Tapping Sequences Scaled Score</measure>
    <time_frame>At 5 years corrected age</time_frame>
    <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: fingertip tapping sequences scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Design Copy Process Total Scaled Score</measure>
    <time_frame>At 5 years corrected age</time_frame>
    <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Design Copy Process Total Scaled Score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Word Reading Standard Score</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Weschler Individual Achievement Test (WIAT-II Abbreviated) to assess the academic skills of the child: Word Reading standard score
Minimum possible score: 45 Maximum possible score: 145
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.
A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numerical Operations Standard Score</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Weschler Individual Achievement Test (WIAT-II Abbreviated) to Assess the Academic Skills of the Child: Numerical Operations standard score
Minimum possible score: 45 Maximum possible score: 145
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.
A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spelling Standard Score</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Weschler Individual Achievement Test (WIAT-II Abbreviated) to Assess the Academic Skills of the Child: Spelling standard score
Minimum possible score: 45 Maximum possible score: 145
A higher score indicates a better outcome.
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers Total Scaled Score</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Children's Memory Scale (CMS):Numbers Total scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Word Lists 1 (Learning) Scaled Score</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Children's Memory Scale (CMS): Word Lists 1 (learning) scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Memory and Learning Word Lists II (Delayed) Scaled Score</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Children's Memory Scale (CMS): Memory and learning Word Lists II (delayed) scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Global Executive Composite (GEC) of the Behaviour Rating of Executive Function</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Full title: The Global Executive Composite (GEC) of the Behaviour Rating of Executive Function
Preschool Version Parent Form (BRIEF-P) to measure behavioural executive abilities.
Minimum possible score: 40 Maximum possible score: 110
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.
A higher score indicates a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Global Adaptive Composite (GAC) of the Adaptive Behavior Assessment System</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Full title: The Global Adaptive Composite (GAC) of the Adaptive Behavior Assessment System
- 2nd edition (ABAS-II) to measure the child's adaptive behavior.
Minimum possible score: 45 Maximum possible score: 145
A higher score indicates a better outcome.
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Problems Score</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Child Behaviour Checklist Caregiver Questionnaire (CBCL): Total Problems Score to measure behavioural problems
Minimum possible score: 40 Maximum possible score: 100
A higher score indicates a worse outcome.
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Internalising Problems T Score</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Child Behaviour Checklist Caregiver Questionnaire (CBCL): CBCL internalising problems T score
Minimum possible score: 40 Maximum possible score: 100
A higher score indicates a worse outcome.
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Externalising Problems T Score</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Child Behaviour Checklist Caregiver Questionnaire (CBCL): externalising problems T score
Minimum possible score: 40 Maximum possible score: 100
A higher score indicates a worse outcome.
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speech or Language Interventions</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Speech or language issues/interventions. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychomotor Interventions</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Psychomotor issues/interventions. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Global Developmental Delay</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Child has global developmental delay. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Attention Deficit Hyperactivity Disorder</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Child has been diagnosed with Attention Deficit Hyperactivity Disorder. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Autism Spectrum Disorder</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Child has been diagnosis with Autism Spectrum Disorder. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Hearing Abnormality</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Child has a hearing abnormality. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Visual Defect in Either Eye</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Child has a visual defect in either eye. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Hearing Aid</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Child has a hearing aid. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Are Legally Blind</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Child is legally blind. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Have Cerebral Palsy</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Child has cerebral palsy. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parents' Awareness of Group Allocation</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>Whether or not a parent is aware of which treatment group their child was allocated to. This variable will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Awareness of Group Allocation by Psychologist</measure>
    <time_frame>At 5 years chronological age</time_frame>
    <description>These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Awareness of Group Allocation by Pediatrician</measure>
    <time_frame>At 5 years chronological age</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">643</enrollment>
  <condition>Inguinal Hernia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regional Anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>General Anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regional Anesthesia</intervention_name>
    <description>Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Spinal Anesthesia.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>General Anesthesia</intervention_name>
    <description>Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>General Anesthesia.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any infant scheduled for unilateral or bilateral inguinal hernia repair (with or
             without circumcision)

          -  Any infant whose gestational age is 26 weeks or more (GA = 182 days)

          -  Any infant whose post-menstrual age is up to 60 weeks (PMA = 426 days)

        Exclusion Criteria:

          -  Any child older than 60 weeks post-menstrual age

          -  Any child born less than 26 weeks gestation

          -  Any contraindication to general or spinal/caudal anesthesia (for example:
             neuromuscular disorder or coagulopathy)

          -  Pre-operative ventilation immediately prior to surgery

          -  Congenital heart disease that has required ongoing pharmacotherapy

          -  Known chromosomal abnormality or any other known acquired or congenital abnormalities
             (apart from prematurity) which are likely to affect development

          -  Children where follow-up would be difficult for geographic or social reasons

          -  Families where English is not the primary language spoken at home

          -  Known neurological injury such as cystic periventricular leukomalacia (PVL), or grade
             3 or 4 intra ventricular hemorrhage (ICH) (+/- post hemorrhage ventricular dilation)

          -  Previous exposure to volatile anesthesia or benzodiazepines as a neonate or in the
             third trimester in utero.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Davidson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Children's Hospital, Victoria, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Ellen McCann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Boston, United States of America</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neil Morton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Hospital for Sick Children, Glasgow, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Hospital Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Iowa Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Children's Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vermont Children's Hospital at Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adelaide Women's and Children's Hospital</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casey Hospital</name>
      <address>
        <city>Berwick</city>
        <state>Victoria</state>
        <zip>3806</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabrini Hospital</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Children's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Sainte-Justine</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G. Gaslini Children's Hospital</name>
      <address>
        <city>Genoa</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>'Vitore Buzzi' Children's Hospital</name>
      <address>
        <city>Milano</city>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelmina Children's Hospital; University Medical Centre Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Starship Children's Health</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Belfast Hospital for Sick Children</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Children's Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2APS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Children's Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2TS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Davidson A, McCann ME, Morton N. Anesthesia neurotoxicity in neonates: the need for clinical research. Anesth Analg. 2007 Sep;105(3):881-2.</citation>
    <PMID>17717261</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 18, 2008</study_first_submitted>
  <study_first_submitted_qc>September 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2008</study_first_posted>
  <results_first_submitted>March 19, 2020</results_first_submitted>
  <results_first_submitted_qc>April 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 29, 2020</results_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children’s Hospital</investigator_affiliation>
    <investigator_full_name>Mary Ellen McCann</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Infants</keyword>
  <keyword>scheduled</keyword>
  <keyword>unilateral</keyword>
  <keyword>bilateral</keyword>
  <keyword>repair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia, Inguinal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 27, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT00756600/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There are no significant events that occur after enrollment and before randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Regional Anesthesia</title>
          <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
        </group>
        <group group_id="P2">
          <title>General Anesthesia</title>
          <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="287"/>
                <participants group_id="P2" count="356"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="287"/>
                <participants group_id="P2" count="356"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Not all patients returned for their follow up visit. For this reason, only 205 participants in the &quot;Regional Anesthesia&quot; group and 242 participants in the &quot;General Anesthesia&quot; group were included in the published analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Regional Anesthesia</title>
          <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
        </group>
        <group group_id="B2">
          <title>General Anesthesia</title>
          <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="287"/>
            <count group_id="B2" value="356"/>
            <count group_id="B3" value="643"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="287"/>
                    <count group_id="B2" value="356"/>
                    <count group_id="B3" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="287"/>
                    <measurement group_id="B2" value="356"/>
                    <measurement group_id="B3" value="643"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="287"/>
                    <count group_id="B2" value="356"/>
                    <count group_id="B3" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.9" spread="30.8"/>
                    <measurement group_id="B2" value="71.1" spread="31.7"/>
                    <measurement group_id="B3" value="70" spread="NA">Data required to calculate the total standard deviation could not be found despite all efforts to locate the underlying data</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="287"/>
                    <count group_id="B2" value="356"/>
                    <count group_id="B3" value="643"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                    <measurement group_id="B2" value="304"/>
                    <measurement group_id="B3" value="536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>Not all patients returned for their follow up visit. For this reason, only 205 participants in the &quot;Regional Anesthesia&quot; group and 242 participants in the &quot;General Anesthesia&quot; group total were included in the published analysis.
The number of participants from each region were the only ones ultimately analyzed and published.</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>New Zealand</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="205"/>
                    <count group_id="B2" value="242"/>
                    <count group_id="B3" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="205"/>
                    <count group_id="B2" value="242"/>
                    <count group_id="B3" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="205"/>
                    <count group_id="B2" value="242"/>
                    <count group_id="B3" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="205"/>
                    <count group_id="B2" value="242"/>
                    <count group_id="B3" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="205"/>
                    <count group_id="B2" value="242"/>
                    <count group_id="B3" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="205"/>
                    <count group_id="B2" value="242"/>
                    <count group_id="B3" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="205"/>
                    <count group_id="B2" value="242"/>
                    <count group_id="B3" value="447"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Full Scale IQ Score</title>
        <description>The primary outcome will be the Wechsler Preschool and Primary Scale of Intelligence-Third Edition (WPPSI-III) full scale IQ score. Verbal, visuo-spatial and processing speed skills are incorporated into the Full Scale IQ score, which is indicative of general intellectual ability.
Minimum score: 45 Maximum score:145 Higher scores are associated with higher IQ scores (better outcome).
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Full Scale IQ Score</title>
          <description>The primary outcome will be the Wechsler Preschool and Primary Scale of Intelligence-Third Edition (WPPSI-III) full scale IQ score. Verbal, visuo-spatial and processing speed skills are incorporated into the Full Scale IQ score, which is indicative of general intellectual ability.
Minimum score: 45 Maximum score:145 Higher scores are associated with higher IQ scores (better outcome).
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.5" spread="14.3"/>
                    <measurement group_id="O2" value="100.1" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Verbal IQ</title>
        <description>Wechsler Preschool and Primary Scale of Intelligence, Third Edition (WPPSI-III): Verbal IQ
Minimum possible score:45 Maximum possible score:145
A higher score indicates higher verbal IQ (better outcome).
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
        <time_frame>At 5 years corrected age.</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Verbal IQ</title>
          <description>Wechsler Preschool and Primary Scale of Intelligence, Third Edition (WPPSI-III): Verbal IQ
Minimum possible score:45 Maximum possible score:145
A higher score indicates higher verbal IQ (better outcome).
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.8" spread="14.7"/>
                    <measurement group_id="O2" value="100.9" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance IQ</title>
        <description>Wechsler Preschool and Primary Scale of Intelligence, Third Edition (WPPSI-III): Performance IQ
Minimum possible score:45 Maximum possible score:145
A higher score indicates a higher performance IQ (better outcome).
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
        <time_frame>At 5 years corrected age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance IQ</title>
          <description>Wechsler Preschool and Primary Scale of Intelligence, Third Edition (WPPSI-III): Performance IQ
Minimum possible score:45 Maximum possible score:145
A higher score indicates a higher performance IQ (better outcome).
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.7" spread="15.2"/>
                    <measurement group_id="O2" value="101.2" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Processing Speed Quotient</title>
        <description>Wechsler Preschool and Primary Scale of Intelligence, Third Edition (WPPSI-III): Processing speed quotient
Minimum possible score:45 Maximum possible score:145
A higher score indicates a better outcome.
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
        <time_frame>At 5 years corrected age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Processing Speed Quotient</title>
          <description>Wechsler Preschool and Primary Scale of Intelligence, Third Edition (WPPSI-III): Processing speed quotient
Minimum possible score:45 Maximum possible score:145
A higher score indicates a better outcome.
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" spread="14.5"/>
                    <measurement group_id="O2" value="96.3" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sentence Repetition Scaled Score</title>
        <description>Developmental Neuropsychological Assessment second edition (NEPSY-II) sub test: Sentence Repetition scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Sentence Repetition Scaled Score</title>
          <description>Developmental Neuropsychological Assessment second edition (NEPSY-II) sub test: Sentence Repetition scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="2.9"/>
                    <measurement group_id="O2" value="9.7" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Auditory Attention Combined Scaled Score</title>
        <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Auditory Attention combined scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
        <time_frame>At 5 years corrected age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Auditory Attention Combined Scaled Score</title>
          <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Auditory Attention combined scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="2.7"/>
                    <measurement group_id="O2" value="9.3" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Statue Scaled Score</title>
        <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Statue scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
        <time_frame>At 5 years corrected age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Statue Scaled Score</title>
          <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Statue scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="3.5"/>
                    <measurement group_id="O2" value="8.6" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inhibition Combined Scaled Score</title>
        <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Inhibition combined scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
        <time_frame>At 5 years corrected age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Inhibition Combined Scaled Score</title>
          <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Inhibition combined scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="3.1"/>
                    <measurement group_id="O2" value="8.9" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Word Generation Scaled Score</title>
        <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Word Generation Scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
        <time_frame>At 5 years corrected age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Word Generation Scaled Score</title>
          <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Word Generation Scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="3.4"/>
                    <measurement group_id="O2" value="9.3" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Affect Recognition Scaled Score</title>
        <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Affect Recognition scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
        <time_frame>At 5 years corrected age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Affect Recognition Scaled Score</title>
          <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Affect Recognition scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="2.8"/>
                    <measurement group_id="O2" value="10.4" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Memory for Names and Memory for Names Delay</title>
        <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Memory for Names and Memory for Names Delay
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
        <time_frame>At 5 years corrected age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Memory for Names and Memory for Names Delay</title>
          <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Memory for Names and Memory for Names Delay
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="3.2"/>
                    <measurement group_id="O2" value="8.1" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Theory of Mind Scaled Score</title>
        <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Theory of Mind scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
        <time_frame>At 5 years corrected age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Theory of Mind Scaled Score</title>
          <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Theory of Mind scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="2.9"/>
                    <measurement group_id="O2" value="9.3" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Speeded Naming Combined Scaled Score</title>
        <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Speeded Naming combined scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
        <time_frame>At 5 years corrected age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia1</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Speeded Naming Combined Scaled Score</title>
          <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Speeded Naming combined scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="3.0"/>
                    <measurement group_id="O2" value="9.8" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fingertip Tapping Repetitions Scaled Score</title>
        <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test:Fingertip tapping repetitions scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score is indicative of a better outcome.</description>
        <time_frame>At 5 years corrected age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Fingertip Tapping Repetitions Scaled Score</title>
          <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test:Fingertip tapping repetitions scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score is indicative of a better outcome.</description>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="3.4"/>
                    <measurement group_id="O2" value="9.7" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fingertip Tapping Sequences Scaled Score</title>
        <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: fingertip tapping sequences scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
        <time_frame>At 5 years corrected age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Fingertip Tapping Sequences Scaled Score</title>
          <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: fingertip tapping sequences scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="3.4"/>
                    <measurement group_id="O2" value="7.7" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Design Copy Process Total Scaled Score</title>
        <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Design Copy Process Total Scaled Score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
        <time_frame>At 5 years corrected age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Design Copy Process Total Scaled Score</title>
          <description>Developmental Neuropsychological Assessment Second Edition (NEPSY-II) Sub Test: Design Copy Process Total Scaled Score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="3.4"/>
                    <measurement group_id="O2" value="9.9" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Word Reading Standard Score</title>
        <description>Weschler Individual Achievement Test (WIAT-II Abbreviated) to assess the academic skills of the child: Word Reading standard score
Minimum possible score: 45 Maximum possible score: 145
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.
A higher score indicates a better outcome.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Word Reading Standard Score</title>
          <description>Weschler Individual Achievement Test (WIAT-II Abbreviated) to assess the academic skills of the child: Word Reading standard score
Minimum possible score: 45 Maximum possible score: 145
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.
A higher score indicates a better outcome.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" spread="18.1"/>
                    <measurement group_id="O2" value="92.8" spread="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numerical Operations Standard Score</title>
        <description>Weschler Individual Achievement Test (WIAT-II Abbreviated) to Assess the Academic Skills of the Child: Numerical Operations standard score
Minimum possible score: 45 Maximum possible score: 145
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.
A higher score indicates a better outcome.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Numerical Operations Standard Score</title>
          <description>Weschler Individual Achievement Test (WIAT-II Abbreviated) to Assess the Academic Skills of the Child: Numerical Operations standard score
Minimum possible score: 45 Maximum possible score: 145
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.
A higher score indicates a better outcome.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" spread="16.2"/>
                    <measurement group_id="O2" value="96.2" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spelling Standard Score</title>
        <description>Weschler Individual Achievement Test (WIAT-II Abbreviated) to Assess the Academic Skills of the Child: Spelling standard score
Minimum possible score: 45 Maximum possible score: 145
A higher score indicates a better outcome.
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Spelling Standard Score</title>
          <description>Weschler Individual Achievement Test (WIAT-II Abbreviated) to Assess the Academic Skills of the Child: Spelling standard score
Minimum possible score: 45 Maximum possible score: 145
A higher score indicates a better outcome.
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.1" spread="13.2"/>
                    <measurement group_id="O2" value="90.8" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numbers Total Scaled Score</title>
        <description>Children's Memory Scale (CMS):Numbers Total scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers Total Scaled Score</title>
          <description>Children's Memory Scale (CMS):Numbers Total scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="3.2"/>
                    <measurement group_id="O2" value="8.1" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Word Lists 1 (Learning) Scaled Score</title>
        <description>Children's Memory Scale (CMS): Word Lists 1 (learning) scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Word Lists 1 (Learning) Scaled Score</title>
          <description>Children's Memory Scale (CMS): Word Lists 1 (learning) scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="3.4"/>
                    <measurement group_id="O2" value="8.6" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Memory and Learning Word Lists II (Delayed) Scaled Score</title>
        <description>Children's Memory Scale (CMS): Memory and learning Word Lists II (delayed) scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Memory and Learning Word Lists II (Delayed) Scaled Score</title>
          <description>Children's Memory Scale (CMS): Memory and learning Word Lists II (delayed) scaled score
Minimum possible score: 1 Maximum possible score: 19
A higher score indicates a better outcome.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="2.8"/>
                    <measurement group_id="O2" value="9.6" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Global Executive Composite (GEC) of the Behaviour Rating of Executive Function</title>
        <description>Full title: The Global Executive Composite (GEC) of the Behaviour Rating of Executive Function
Preschool Version Parent Form (BRIEF-P) to measure behavioural executive abilities.
Minimum possible score: 40 Maximum possible score: 110
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.
A higher score indicates a worse outcome.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>The Global Executive Composite (GEC) of the Behaviour Rating of Executive Function</title>
          <description>Full title: The Global Executive Composite (GEC) of the Behaviour Rating of Executive Function
Preschool Version Parent Form (BRIEF-P) to measure behavioural executive abilities.
Minimum possible score: 40 Maximum possible score: 110
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.
A higher score indicates a worse outcome.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.4" spread="12.5"/>
                    <measurement group_id="O2" value="51.5" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Global Adaptive Composite (GAC) of the Adaptive Behavior Assessment System</title>
        <description>Full title: The Global Adaptive Composite (GAC) of the Adaptive Behavior Assessment System
- 2nd edition (ABAS-II) to measure the child's adaptive behavior.
Minimum possible score: 45 Maximum possible score: 145
A higher score indicates a better outcome.
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>The Global Adaptive Composite (GAC) of the Adaptive Behavior Assessment System</title>
          <description>Full title: The Global Adaptive Composite (GAC) of the Adaptive Behavior Assessment System
- 2nd edition (ABAS-II) to measure the child's adaptive behavior.
Minimum possible score: 45 Maximum possible score: 145
A higher score indicates a better outcome.
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" spread="16.3"/>
                    <measurement group_id="O2" value="94.1" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Problems Score</title>
        <description>Child Behaviour Checklist Caregiver Questionnaire (CBCL): Total Problems Score to measure behavioural problems
Minimum possible score: 40 Maximum possible score: 100
A higher score indicates a worse outcome.
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Problems Score</title>
          <description>Child Behaviour Checklist Caregiver Questionnaire (CBCL): Total Problems Score to measure behavioural problems
Minimum possible score: 40 Maximum possible score: 100
A higher score indicates a worse outcome.
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6" spread="11.7"/>
                    <measurement group_id="O2" value="46.7" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Internalising Problems T Score</title>
        <description>Child Behaviour Checklist Caregiver Questionnaire (CBCL): CBCL internalising problems T score
Minimum possible score: 40 Maximum possible score: 100
A higher score indicates a worse outcome.
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Internalising Problems T Score</title>
          <description>Child Behaviour Checklist Caregiver Questionnaire (CBCL): CBCL internalising problems T score
Minimum possible score: 40 Maximum possible score: 100
A higher score indicates a worse outcome.
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1" spread="12.5"/>
                    <measurement group_id="O2" value="48.0" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Externalising Problems T Score</title>
        <description>Child Behaviour Checklist Caregiver Questionnaire (CBCL): externalising problems T score
Minimum possible score: 40 Maximum possible score: 100
A higher score indicates a worse outcome.
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Externalising Problems T Score</title>
          <description>Child Behaviour Checklist Caregiver Questionnaire (CBCL): externalising problems T score
Minimum possible score: 40 Maximum possible score: 100
A higher score indicates a worse outcome.
Note: Scale ranges represent estimates that are very likely to be accurate but which will be verified after access to the physical assessment booklets is restored. The current health situation prohibits the research team from verifying this information at the moment.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0" spread="10.7"/>
                    <measurement group_id="O2" value="45.8" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Speech or Language Interventions</title>
        <description>Speech or language issues/interventions. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Speech or Language Interventions</title>
          <description>Speech or language issues/interventions. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psychomotor Interventions</title>
        <description>Psychomotor issues/interventions. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Psychomotor Interventions</title>
          <description>Psychomotor issues/interventions. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Global Developmental Delay</title>
        <description>Child has global developmental delay. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Global Developmental Delay</title>
          <description>Child has global developmental delay. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Attention Deficit Hyperactivity Disorder</title>
        <description>Child has been diagnosed with Attention Deficit Hyperactivity Disorder. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Attention Deficit Hyperactivity Disorder</title>
          <description>Child has been diagnosed with Attention Deficit Hyperactivity Disorder. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Autism Spectrum Disorder</title>
        <description>Child has been diagnosis with Autism Spectrum Disorder. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Autism Spectrum Disorder</title>
          <description>Child has been diagnosis with Autism Spectrum Disorder. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Hearing Abnormality</title>
        <description>Child has a hearing abnormality. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Hearing Abnormality</title>
          <description>Child has a hearing abnormality. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="252"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Visual Defect in Either Eye</title>
        <description>Child has a visual defect in either eye. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Visual Defect in Either Eye</title>
          <description>Child has a visual defect in either eye. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Hearing Aid</title>
        <description>Child has a hearing aid. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Hearing Aid</title>
          <description>Child has a hearing aid. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Are Legally Blind</title>
        <description>Child is legally blind. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Are Legally Blind</title>
          <description>Child is legally blind. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Have Cerebral Palsy</title>
        <description>Child has cerebral palsy. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Have Cerebral Palsy</title>
          <description>Child has cerebral palsy. These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
          <population>Not all participants had data collected for this Outcome Measure due to absence at follow up visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parents' Awareness of Group Allocation</title>
        <description>Whether or not a parent is aware of which treatment group their child was allocated to. This variable will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Parents' Awareness of Group Allocation</title>
          <description>Whether or not a parent is aware of which treatment group their child was allocated to. This variable will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
          <units>caregivers</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="356"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Awareness of Group Allocation by Psychologist</title>
        <description>These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
        <time_frame>At 5 years chronological age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Awareness of Group Allocation by Psychologist</title>
          <description>These variables will be summarised using descriptive statistics by treatment arm only. No treatment effect or confidence intervals will be calculated.</description>
          <units>psychologists</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="356"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Awareness of Group Allocation by Pediatrician</title>
        <time_frame>At 5 years chronological age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Regional Anesthesia</title>
            <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
          </group>
          <group group_id="O2">
            <title>General Anesthesia</title>
            <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Awareness of Group Allocation by Pediatrician</title>
          <units>Pediatricians</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="356"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were not monitored/assessed</time_frame>
      <desc>Adverse Events were not monitored/assessed</desc>
      <group_list>
        <group group_id="E1">
          <title>Regional Anesthesia</title>
          <description>Regional Anesthesia: Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.</description>
        </group>
        <group group_id="E2">
          <title>General Anesthesia</title>
          <description>General Anesthesia: Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Mary Ellen McCann</name_or_title>
      <organization>Boston Children's Hospital Anesthesia Foundation</organization>
      <phone>6173557737</phone>
      <email>mary.mccann@childrens.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

